Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 29, 2022

SELL
$11.56 - $19.76 $114,478 - $195,683
-9,903 Reduced 19.81%
40,097 $652,000
Q3 2021

Oct 21, 2021

BUY
$14.21 - $17.65 $710,500 - $882,499
50,000 New
50,000 $719,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Park Avenue Securities LLC Portfolio

Follow Park Avenue Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Park Avenue Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Park Avenue Securities LLC with notifications on news.